News Releases News Releases HOME HOME

August 19, 2004

Launch of Multi-Symptom Cold Relief "Pabron AG Tablet" Contains Mequitazine to Reduce Sneezing, a Runny Nose and Nasal Congestion


Taisho Pharmaceutical Co., Ltd. (President: Akira Uehara) will release Pabron AG Tablet on August 23. This cold and flu medication is particularly effective for the relief of sneezing, a runny nose and nasal congestion.

Pabron AG Tablet has antiallergic and antihistamic effects. It is the first Pabron preparation to include mequitazine, which is well known for its effectiveness in alleviating symptoms such as sneezing, a runny nose and nasal congestion. Pabron AG Tablet also contains 7 other active ingredients, including bromhexine hydrochloride, to effectively alleviate various cold symptoms. These tablets are small, and therefore easy to take. 

In 1927, Taisho Pharmaceutical released Pabron as a cough suppressant and expectorant. Since then, we have been responding to the needs of consumers by extending the range of products in the Pabron series, improving ingredients, and developing new products. The Pabron brand provides a comprehensive selection of cold and flu medications. The release of Pabron AG Tablet will strengthen the Pabron series for cold and flu relief. 

Product features
- Contains mequitazine, which has antiallergic and antihistamic effects
- Small, easy-to-take tablets
- Cold and flu medication for adults (15 years or older)

Product specification
Product name Pabron AG Tablet
Suggested retail price 110 tablets ¥2,604  45 tablets ¥1,239 
 (tax included)
Ingredients (in every 3 tablets)
Mequitazine 1.33mg
(4mg in 9 tablets)
Acetaminophen 300mg
Bromhexine hydrochloride 4mg
Dihydrocodeine phosphate 8mg
dl-methylephedrine hydrochloride 20mg
Anhydrate caffeine 25mg
Thiamine mononitrate (vitamin B1) 8mg
Vitamin B2 4mg
Indications Alleviates various cold symptoms (runny nose, nasal congestion, sneezing, sore throat, cough, sputum, chill, fever, headache, joint pain, muscle pain)
Dosage Take the following dose within 30 minutes following meals. 
Age 15 years or older Less than 15 years
Dose 3 tablets Do not take the drug.
Frequency 3 times a day
Date of sale August 23, 2004
Expected sales ¥800 million (one year from date of sale)